1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Dulaglutide |
| brand | String | Trulicity |
| structure | File | |
| classes | List of String, delimiter: , | [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · Fc-fusion biologic |
| mechanism | String | Long-acting agonist of the [[GLP-1 receptor]]; Fc-fusion construct. |
| uses | String | [[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM |
| starting_dose | String | 0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' |
| preparations | String | Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"' |
| fda_max | String | 4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"' |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous (abdomen • thigh • upper arm)'"`UNIQ--ref-00000056-QINU`"' |
| onset | String | Glycemic effect within days; near-maximal HbA1c effect by 4 weeks at any given dose'"`UNIQ--ref-00000057-QINU`"' |
| duration | String | ~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"' |
| halflife | String | ~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"' |
| bioavailability | String | SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' |
| pregnancy | String | Avoid. Discontinue at least 1 month before planned pregnancy. Animal data show embryofetal harm.'"`UNIQ--ref-0000005B-QINU`"' |
| legal | String | Rx-only;'"`UNIQ--ref-0000005C-QINU`"' not a controlled substance |
